Log in to search using one of your social media accounts:

 

Waiting to Treat the Cancer

It would be a race between the leukemia returning and the insurance company approving the procedure that could keep it at bay permanently.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Leukemia Transplants Bone Marrow Health Insurance and Managed Care Chemotherapy Testicles Cancer Source Type: news

Related Links:

For as long as he can remember, Josh Feldman has eagerly embraced the latest technology.Decades ago, his family was the first one on the block with a VCR. Years later, when television went hi-def, he acquired a big-screen TV and signed up for HD service.So after he was diagnosed with lymphoma, it was only natural that Feldman was driven to join clinical trials for a promising new treatment. He would become one of the first UCLA Health patients to receive CAR T therapy. When nothing else worked, the treatment beat back cancer and filled his life with new hope.“Years ago, while doing my own reading after my diagnosis, ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Last year, the Food and Drug Administration approved two new immunotherapies to treat certain leukemias and lymphomas. Now, in a study published in the New England Journal of Medicine, researchers detail who is most likely to benefit from the treatments, called CAR T cell therapy. CAR T cell therapy trains the body’s immune system to target and destroy cancer cells in the blood; scientists take people’s own immune cells (T cells) and genetically engineer them to seek out and destroy cancer cells. The immune system can then attack cancer cells in the same way it does bacteria and viruses, and the therapy can lea...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer cancer cells cancer immunotherapy CAR T car t cell therapy car t gene therapy car t therapy cure for cancer healthytime leukemia leukemia treatments Source Type: news
Immunotherapy is a cut above chemotherapy and radiotherapy: at its best, it is significantly more effective and significantly less harmful to the patient. It has still required years, a great deal of funding, and many failures for those best approaches to arise. Nonetheless, the report here is a cheering example for the sizable fraction of us expected to suffer cancer at some point in the years ahead if the condition is not soon brought under medical control. This immunotherapy appears highly effective, and just importantly, adaptable to many types of cancer. This potential for broad application is the most important aspec...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
In January, 2018, Academic Press published my bookPrecision Medicine and the Reinvention of Human Disease. This book has an excellent " look inside " at itsGoogle book site, which includes the Table of Contents. In addition, I thought it might be helpful to see the topics listed in the Book's index. Note that page numbers followed by f indicate figures, t indicate tables, and ge indicate glossary terms.AAbandonware, 270, 310geAb initio, 34, 48ge, 108geABL (abelson leukemia) gene, 28, 58ge, 95 –97Absidia corymbifera, 218Acanthameoba, 213Acanthosis nigricans, 144geAchondroplasia, 74, 143ge, 354geAcne, 54ge, 1...
Source: Specified Life - Category: Information Technology Tags: index jules berman jules j berman precision medicine Source Type: blogs
It took a team of UCLA medical professionals and the generosity of 71 strangers to save 2-year-old Skye Savren-McCormick ’s life.The toddler from Ventura, California, required frequent blood and platelet transfusions, often on a daily basis, while undergoing  three grueling bone-marrow transplants, surgery to remove her swollen spleen and seven rounds of chemotherapy for leukemia and lymphoma. She received 77 units of blood and platelets during a 10-month stay at UCLA Mattel Children ’s Hospital.  Recently Skye ’s family got to meet and thank two dozen of the 71 strangers whose blood a...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
A higher risk for a variety of cancers is among the major complications of posttransplantation immunosuppression. In this part of a continuing series on cancers posttransplantation, this review focuses on the hematologic cancers after solid organ transplantation. Posttransplantation lymphoproliferative disorders (PTLDs), which comprise the great majority of hematologic cancers, represent a spectrum of conditions that include, but are not limited to, the Hodgkin and non‐Hodgkin lymphomas. The oncogenic Epstein‐Barr virus is a key pathogenic driver in many PTLD cases, through known and unknown mechanisms. The other hemat...
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Tags: COMPREHENSIVE REVIEW Source Type: research
AbstractInduction of complete remission (CR) is imperative for long-term survival in adult acute lymphoblastic leukemia (ALL) patients regardless of transplantation eligibility. Hyper-CVAD chemotherapy is a widely-used frontline remission induction regimen for these patients. We conducted a pilot trial of frontline remission induction using daunorubicin-augmented hyper-CVAD regimen (hyper-CVDD) in adult ALL patients (n = 15). The CR rate after this modified regimen was 100% (n = 15). Twelve patients were able to proceed to allogeneic hematopoietic cell transplantation, two patients died before t...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
​​BY ​​​GURDEEP​ SINGH NAGI, MD; BHAVINI TAILOR, ​MD; & ​AHMED RAZIUDDIN, MDA 40-year-old man with no significant past medical history presented to the emergency department with visual problems. He said he had noticed about four days earlier a dark red circle over any object on which he tried to focus. The condition had been constant and had not improved or worsened over the past few days. He also said it did not matter whether he was focusing on an object that was near or far.The patient had seen an optometrist who recommended he have blood work done, but did not specify what exactly to test...
Source: The Case Files - Category: Emergency Medicine Tags: Blog Posts Source Type: research
Conclusion Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients. Micro-Abstract We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our res...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion CLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML. Micro-Abstract Given the lack of standard salvage chemotherapy regimen for relapsed or refractory (RR) acute myeloid leukemia (AML), a phase 2 clinical study of cladribine, cytarabine, G-CSF (CLAG) regimen in combination with imatinib mesylate (IM) in patients with RR-AML was conducted at the Moffitt Cancer Center. Between August 2009 and April 2011, 38 patients were treated and the overall response rate was 37% with a median overall survival of 11.1 month. Among responders, 8/14 patients proceeded to allogeneic h...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Health Insurance | Insurance | Insurers | Leukemia | Managed Care | Transplants